… role of extracorporeal photopheresis (ECP) in chronic GVHD … ECP for moderate or
severe cGVHD. Response was … at 6 months using the chronic GVHD symptom scale (cGVHD …

… and T-cell-mediated diseases, including scleroderma and cutaneous T-cell lymphoma/Sézary
syndrome (CTCL), severe generalized atopic dermatitis, erosive oral lichen planus and …

Background/Objectives: Graft-versus-host disease (GVHD) is a severe complication of …
Extracorporeal photopheresis (ECP) is considered as a second-line treatment administered …

… Later, studies reported efficacy of this treatment in autoimmune-mediated disorders, progressive
systemic sclerosis, GVHD and allograft rejection. Two recent studies reported results of …

… Extracorporeal photopheresis (ECP) is a treatment option when GVHD becomes refractory
or dependent on first-line steroids [4,5]. The sequence of an ECP session is as follows: …

… (bone marrow suppression, severe infections) ( 6 ). Extracorporeal photopheresis is a cell-…
mediated diseases such as rheumatoid arthritis ( 9 ), systemic sclerosis ( 10 ), and graft-versus-…

… Extracorporeal photopheresis (ECP) is an autologous cell therapy that is widely used for the
… , such as rheumatoid arthritis, psoriasis, systemic sclerosis, type 1 diabetes, and Crohn’s …

… Skin features with cGVHD range from acute erythematous rash to chronic sclerosis. There
are few reported cases of sclerodermatous cGVHD in children, and, in the pediatric population…

… Extracorporeal photopheresis (ECP) is a safe and effective immunoregulatory therapy for
steroid-refractory chronic … sclerosis, we divided ECP-treated patients into four groups: aGVHD− …

… › Extracorporeal photopheresis appears to be an effective … and chronic GVHD) as well as
solid organ transplantation and selected T-cell-mediated diseases such as systemic sclerosis …